{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=27", "query": { "intervention": "Period C", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 882, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:33:39.952Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04515628", "title": "Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Branebrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 22, "start_date": "2020-08-02", "completion_date": "2020-10-26", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04515628" }, { "nct_id": "NCT01594619", "title": "Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Induced Constipation" ], "interventions": [ { "name": "Naloxegol", "type": "DRUG" }, { "name": "Diltiazem XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2012-05", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2014-10-15", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594619" }, { "nct_id": "NCT06609226", "title": "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease", "Thalassemia" ], "interventions": [ { "name": "Etavopivat A", "type": "DRUG" }, { "name": "Etavopivat B", "type": "DRUG" }, { "name": "Etavopivat C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 480, "start_date": "2025-01-10", "completion_date": "2030-12-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06609226" }, { "nct_id": "NCT06378658", "title": "A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non-small Cell Lung Cancer", "EGFR Mutation", "HER2 Mutation", "Healthy Volunteers" ], "interventions": [ { "name": "BAY2927088", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Food", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2024-03-29", "completion_date": "2024-06-11", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06378658" }, { "nct_id": "NCT04888585", "title": "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "ABBV-154", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 473, "start_date": "2021-06-23", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 101, "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04888585" }, { "nct_id": "NCT02699450", "title": "A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2016-04-27", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02699450" }, { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT04586985", "title": "Safety, Tolerability and Pharmacokinetics of FTX-6058", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Subjects", "Sickle Cell Disease" ], "interventions": [ { "name": "FTX-6058/placebo oral capsule(s)", "type": "DRUG" }, { "name": "FTX-6058 - Two Dosing Periods", "type": "DRUG" }, { "name": "FTX-6058 / Midazolam Syrup", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fulcrum Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 109, "start_date": "2020-10-26", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2022-12-12", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Overland Park, Kansas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04586985" }, { "nct_id": "NCT02559817", "title": "A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome With Constipation" ], "interventions": [ { "name": "Linaclotide Dose A", "type": "DRUG" }, { "name": "Linaclotide Dose B", "type": "DRUG" }, { "name": "Linaclotide Dose C", "type": "DRUG" }, { "name": "Linaclotide Approved Adult Dose", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "7 Years to 17 Years" }, "enrollment_count": 101, "start_date": "2015-11-01", "completion_date": "2019-08-30", "has_results": true, "last_update_posted_date": "2020-12-28", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 46, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559817" }, { "nct_id": "NCT02411500", "title": "A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TRV734", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trevena Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 18, "start_date": "2015-02", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-10-31T12:33:39.952Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411500" } ] }